WO2019098518A1 - Method for preparing green tea extract and green tea extract prepared therefrom - Google Patents
Method for preparing green tea extract and green tea extract prepared therefrom Download PDFInfo
- Publication number
- WO2019098518A1 WO2019098518A1 PCT/KR2018/010949 KR2018010949W WO2019098518A1 WO 2019098518 A1 WO2019098518 A1 WO 2019098518A1 KR 2018010949 W KR2018010949 W KR 2018010949W WO 2019098518 A1 WO2019098518 A1 WO 2019098518A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- green tea
- tea extract
- flavonol
- catechin
- weight
- Prior art date
Links
- 235000020688 green tea extract Nutrition 0.000 title claims abstract description 116
- 229940094952 green tea extract Drugs 0.000 title claims abstract description 114
- 238000000034 method Methods 0.000 title claims abstract description 42
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims abstract description 71
- 235000005487 catechin Nutrition 0.000 claims abstract description 71
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims abstract description 65
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims abstract description 47
- 229950001002 cianidanol Drugs 0.000 claims abstract description 47
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 claims abstract description 45
- 235000011957 flavonols Nutrition 0.000 claims abstract description 45
- 150000007946 flavonol Chemical class 0.000 claims abstract description 41
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 22
- 235000004515 gallic acid Nutrition 0.000 claims abstract description 22
- 229940074391 gallic acid Drugs 0.000 claims abstract description 22
- 239000002537 cosmetic Substances 0.000 claims abstract description 12
- 235000013305 food Nutrition 0.000 claims abstract description 8
- 102000004190 Enzymes Human genes 0.000 claims description 39
- 108090000790 Enzymes Proteins 0.000 claims description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 102000004889 Interleukin-6 Human genes 0.000 claims description 19
- 108090001005 Interleukin-6 Proteins 0.000 claims description 19
- 244000269722 Thea sinensis Species 0.000 claims description 19
- 229940100601 interleukin-6 Drugs 0.000 claims description 19
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 18
- 235000009569 green tea Nutrition 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 14
- 102000000589 Interleukin-1 Human genes 0.000 claims description 13
- 108010002352 Interleukin-1 Proteins 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 229930182830 galactose Natural products 0.000 claims description 12
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 11
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 9
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 9
- 235000005875 quercetin Nutrition 0.000 claims description 9
- 229960001285 quercetin Drugs 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims description 6
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims description 6
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims description 6
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims description 6
- 235000012734 epicatechin Nutrition 0.000 claims description 6
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 230000001788 irregular Effects 0.000 claims description 5
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 abstract 1
- 229940088598 enzyme Drugs 0.000 description 30
- -1 catechin (C) Chemical class 0.000 description 21
- 150000001765 catechin Chemical class 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 12
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 11
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 235000008504 concentrate Nutrition 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 5
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- 102000015790 Asparaginase Human genes 0.000 description 4
- 108010024976 Asparaginase Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 229960003272 asparaginase Drugs 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- XUDNWQSXPROHLK-OACYRQNASA-N 2-phenyl-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=CC=CC=2)OC2=CC=CC=C2C1=O XUDNWQSXPROHLK-OACYRQNASA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000209507 Camellia Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000018597 common camellia Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 235000008777 kaempferol Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 2
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 2
- 235000007743 myricetin Nutrition 0.000 description 2
- 229940116852 myricetin Drugs 0.000 description 2
- 229940105132 myristate Drugs 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- LSHVYAFMTMFKBA-PZJWPPBQSA-N (+)-catechin-3-O-gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-PZJWPPBQSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- XMOCLSLCDHWDHP-DOMZBBRYSA-N (-)-gallocatechin Chemical compound C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-DOMZBBRYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- VQWFNAGFNGABOH-UHFFFAOYSA-K chromium(iii) hydroxide Chemical compound [OH-].[OH-].[OH-].[Cr+3] VQWFNAGFNGABOH-UHFFFAOYSA-K 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940050549 fiber Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 239000010881 fly ash Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000015206 pear juice Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229940057977 zinc stearate Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
Definitions
- the present invention relates to a method for preparing green tea extract and a green tea extract prepared therefrom, and more particularly, to a method for preparing green tea extract having an increased amount of aspartic acid of gallic acid, non-gallate catechin and flavonol, .
- the tea is a sprout or leaf of Camellia sinensis O, Kuntze, which belongs to Camellia (Camellia) and contains 75-80% moisture and 20-25% solids.
- Solid contents include various organic compounds such as catechin, caffeine, amino acid, fiber, and pectin, lipid, resin, essential oil, vitamin, chlorophyll and the like.
- These ingredients form a unique taste and flavor of tea, and particularly have physiological activity effects such as inhibition of cholesterol elevation by catechins, inhibition of blood sugar increase, inhibition of arteriosclerosis, antioxidant activity, antibacterial activity, antiulcer activity and mutation inhibition Scientifically identified, the value of health beverages and functional foods is being reassessed.
- Green tea contains a large amount of antioxidant catechin, which is known to inhibit oxidation of low density lipoproteins in the human body and to inhibit cholesterol biosynthesis.
- Catechin is a generic term for catechins contained in green tea and catechins such as catechin (C), gallocatechin (GC), epicatechin (EC), epigallocatechin (EGC), epicatechin Epicatechallocatechin gallate (EGCG), epigallocatechin gallate is the most abundant, and its physiological activity is also known to be the highest.
- the flavor of the green tea extract is improved by controlling the ratio of non-gallate catechins containing no gallate, and an efficient production technique of green tea extract having a high gallate catechin ratio is known,
- the production method of green tea extract having a high gallate catechin ratio is not known.
- An object of the present invention is to provide a method for preparing green tea extract having an excellent anti-inflammatory effect by increasing the content of asparagine of gallic acid, non-galactic catechin and flavonol.
- the present invention is a.
- the enzyme is a complex enzyme comprising glucanase and arabinase.
- the present invention also provides a green tea extract prepared by the method of the present invention.
- the present invention also provides an anti-inflammatory cosmetic composition comprising the green tea extract of the present invention as an active ingredient.
- the present invention also provides a pharmaceutical composition for antiinflammation comprising the green tea extract of the present invention as an active ingredient.
- the present invention also provides an anti-inflammatory food composition containing the green tea extract of the present invention as an active ingredient.
- the method for preparing green tea extract of the present invention can increase the content of asparaginase of gallic acid, non-galactose catechin, and flavonol in green tea extract, and thus it can exhibit excellent anti-inflammatory effect.
- the green tea extract prepared by the method of the present invention is excellent in anti-inflammatory effect and can be used as an anti-inflammatory food composition, a cosmetic composition and a pharmaceutical composition.
- FIG. 1 is a graph showing the degree of mRNA expression of interleukin-1? (IL-1?) In cells treated with green tea extract prepared in Example 1 and Comparative Example 1.
- FIG. 1 is a graph showing the degree of mRNA expression of interleukin-1? (IL-1?) In cells treated with green tea extract prepared in Example 1 and Comparative Example 1.
- FIG. 2 is a graph showing the degree of mRNA expression of interleukin-6 (IL-6) in cells treated with green tea extract prepared in Example 1 and Comparative Example 1.
- FIG. 1 is a graph showing the degree of mRNA expression of interleukin-6 (IL-6) in cells treated with green tea extract prepared in Example 1 and Comparative Example 1.
- FIG. 1 is a graph showing the degree of mRNA expression of interleukin-6 (IL-6) in cells treated with green tea extract prepared in Example 1 and Comparative Example 1.
- FIG. 3 is a graph showing the degree of mRNA expression of cyclooxygenase-2 (COX-2) in cells treated with green tea extract prepared in Example 1 and Comparative Example 1.
- COX-2 cyclooxygenase-2
- FIG. 4 is a graph showing the content of catechins transferred into cells of the green tea extract prepared in Example 1.
- the present invention relates to a method for preparing an green tea extract having increased amounts of an aspartic acid of gallic acid, non-gallate catechin and flavonol,
- the enzyme is a complex enzyme including glucanase and arabinase.
- Gallic acid is a substance produced by hydrolysis of tannin. It is also used as a natural antioxidant and has been known to have such effects as obesity, antioxidant, hypertension, antibacterial, anti-inflammatory, blood glucose control, dyslipidemia and liver function .
- Non-gallate catechin is known to exhibit an anti-inflammatory effect in catechins, a type of flavonoid, which does not contain gallate.
- the antiserum of flavonol includes myricetin, quercetin and kaempferol.
- the myristate, quercetin and camphorol have excellent physiological activities such as antioxidant and anti-inflammation, and the absorption of catechin , And various applications have been made in various fields.
- the present invention provides a method for preparing green tea extract having an excellent anti-inflammatory effect by increasing the content of galactic acid, non-galactic catechin and an unglycoside of flavonol.
- the step (a) is a step of preparing green tea extract.
- the green tea may be one prepared by a conventional ordinary method, and the green tea may include at least one selected from the group consisting of green tea leaves, green tea leaves and green tea roots, have.
- the green tea extract is prepared using an extraction solvent, and the extraction solvent includes at least one selected from the group consisting of water, an alcohol having 1 to 5 carbon atoms and ethyl acetate, and is preferably composed of water and ethanol And at least one selected from the group consisting of
- the extraction temperature and the extraction time are not particularly limited, but the extraction temperature is preferably room temperature to 80 ° C, and the extraction time is 1 to 5 hours.
- the green tea extract of step (a) can be extracted by various methods using the above-mentioned extraction solvent.
- water of about 10 to 30 times the weight of the green tea is added and subjected to primary extraction at 100 ° C. for 4 hours, followed by secondary extraction for 4 hours in the same manner,
- the combined extracts are filtered, and the filtrate is concentrated with a concentrator.
- the concentrated extract is dried using a spray drying or vacuum freeze-freeze dryer.
- 70% ethanol extract is prepared by adding 70% ethanol of about 10 to 30 times the weight of green tea, extracting the mixture at 50 to 80 ° C for 30 minutes to 3 hours, filtering and concentrating the filtrate with a concentrator do.
- the concentrated extract is dried using a spray drying or vacuum freeze-freeze dryer.
- 95% ethanol extract is prepared by adding 95% ethanol of about 10 to 30 times the weight of green tea, allowing to stand at room temperature for 1 to 3 days (shaking operation is repeated every 6 hours) , And the same procedure is repeated twice to obtain an extract.
- the primary and secondary extracts are combined and filtered, and the filtrate is concentrated with a concentrator.
- the concentrated extract is dried using a spray drying or vacuum freeze-freeze dryer.
- the step (b) is a step of reacting the green tea extract and the enzyme produced in the step (a).
- the enzyme is a complex enzyme, and contains glucanase (enzyme code number 3.2.1.6) derived from a black mold ( Aspergillus niger ) and arabinanase (enzyme code number 3.2.1.99).
- the complex enzyme hydrolyzes the sugar, and by reacting the green tea extract with the complex enzyme, the flavonol glycoside contained in the green tea extract can be hydrolyzed to increase the content of the flavonol sugar.
- the content of non-galactose catechins and gallic acid can be increased by decalizing catechin compounds including gallate among the catechins contained in the green tea extract.
- the complex enzyme is contained in an amount of 3 to 30% by weight, preferably 5 to 15% by weight based on the total weight of the green tea extract prepared in the step (a).
- the complex enzyme comprises glucanase and arabinanase in a weight ratio of 1:10 to 10: 1, preferably in a weight ratio of 1: 5 to 5: 1.
- the sugar of the flavonol glycoside and gallate of the catechin can be simultaneously hydrolyzed by more than a predetermined amount during the enzyme reaction time.
- the green tea extract and the complex enzyme may be reacted at 20 to 60 ° C for 12 to 48 hours, preferably 30 to 50 ° C for 20 to 30 hours.
- the green tea extract and the complex enzyme can hydrolyze the sugar bound to flavonol and hydrolyze the gallate of catechin as the reaction is carried out at 20 to 60 ° C for 12 to 48 hours, And the content of non-galactose catechins can be increased. However, if the temperature range is exceeded, the complex enzyme may not function properly or may be inactivated. Also, the hydrolysis is sufficient within the reaction time to increase the content of flavonol aspartate and non-galactate catechin. However, after the reaction time, the catechins are oxidized to decrease the content of non-galactose catechin can do.
- the present invention may further include the step of inactivating the complex enzyme after reacting the green tea extract and the complex enzyme.
- the deactivation may be performed at 50 to 90 ° C for 10 minutes to 3 hours, preferably at 65 to 80 ° C for 30 minutes to 1 hour.
- the present invention may further include a step of removing sugar from the green tea extract prepared in the step (b).
- the method may further include a step of concentrating the green tea extract prepared in step (b) to prepare a concentrate, and then removing sugar from the concentrate.
- the green tea extract and the complex enzyme are reacted and then filtered to concentrate the filtrate with a concentrator to prepare a concentrate. At this time, it is preferable that the concentrated liquid contains about 10% by weight of solids.
- the method of removing the sugar is not particularly limited, in the present invention, it is preferable to separate and remove sugar using chromatography.
- the concentrate is adsorbed on a column equipped with an adsorption resin, and is washed with water 2 to 5 times the column volume and eluted with 2 to 5 times of the alcohol to obtain a green tea fraction.
- the fraction may be concentrated and lyophilized to prepare a green tea extract.
- the lyophilization method is not particularly limited, and may be performed by a method known in the art.
- the method for preparing green tea extract of the present invention can provide a method for preparing green tea extract having increased content of asparaginase of gallic acid, non-gallate catechin and flavonol. Among them, A manufacturing method can be provided.
- the non-galactose catechins refer to catechins not containing galate among catechins, and the non-gallyate catechins include gallocatechin, epigallocatechin, catechin, and epicatechin.
- the antiserum of flavonol includes prednisine, quercetin and camphorol.
- the green tea extract contains 2 to 10% by weight of gallic acid and 20 to 60% by weight of non-gallate catechin based on the total weight of the green tea extract, and contains 4 to 15 mg / g of irregular body of flavonol.
- non-galactose catechins are included in an amount of 70 to 100% by weight based on the total weight of the catechins.
- the glycans, the non-galactose catechins and the antigens of flavonols have anti-inflammatory effects. Therefore, in the present invention, the anti-inflammatory effect can be exhibited by increasing the content of galactic acid, non-galactose catechin, and flavonol in the green tea extract. In addition, since the irregular body of the flavonol promotes the absorption of catechins, the anti-inflammatory effect can be maximized by increasing the content of the irreversible body of flavonol.
- IL-1 interleukin-6
- COX-2 cyclooxygenase-2
- the present invention also relates to green tea extract prepared by the production method of the present invention.
- the green tea extract of the present invention has higher content of non-saccharides of gallic acid, non-galactic catechin and flavonol than that of the conventional green tea extract. Especially, the content of fly ash is higher than that of the conventional green tea extract.
- it contains 2 to 10% by weight of gallic acid and 20 to 60% by weight of non-gallate catechin based on the total weight of the green tea extract, and contains 4 to 15 mg / g of irregular body of flavonol.
- the green tea extract of the present invention inhibits the expression of at least one selected from the group consisting of interleukin-1? (IL-1?), Interleukin-6 (IL-6) and cyclooxygenase- Activity can be exhibited.
- IL-1? interleukin-1?
- IL-6 Interleukin-6
- cyclooxygenase- Activity can be exhibited.
- the green tea extract of the present invention can exhibit anti-inflammatory effect.
- the present invention also relates to an anti-inflammatory cosmetic composition containing the green tea extract of the present invention as an active ingredient.
- the cosmetic composition for anti-inflammation may be used as an active ingredient of functional cosmetics.
- the content of the green tea extract contained in the functional cosmetics is not particularly limited, and may be, for example, 0.01 to 99.9% by weight.
- the functional cosmetic of the present invention may further comprise cosmetics conventionally used as an active ingredient of the green tea extract.
- glycerol propylene glycol, 1,3-butylene glycol
- a surfactant such as sorbitol, polyethylene glycol, carboxyvinyl polymer, xanthan gum, carboxymethylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, locust bean gum, allantoin, carrageenan, Aluminum stearate, zinc stearate, and witchhazel can be used.
- a surfactant such as sorbitol, polyethylene glycol, carboxyvinyl polymer, xanthan gum, carboxymethylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, locust bean gum, allantoin, carrageenan, Aluminum stearate, zinc stearate, and witchhazel
- the ultraviolet absorber butylmethoxydibenzoylmethane, octylmethoxycinnamate,
- titanium dioxide As the pigment, there can be used titanium dioxide, particulate ditanium dioxide, ka Coloring pigments such as yellow iron oxide, black iron oxide, red iron oxide, ultramarine, chromium oxide and chromium hydroxide can be used as extender pigments such as rhenium, nylon powder, talc, sericite, mica and polymethyl methacrylate, Natural moisturizing substances such as chitin, chitosan, hyaluronic acid, hyaluronic acid, lactic acid, glycolic acid and the like can be used, and as a preservative, paraoxybenzoic acid esters, imida Zoledinyl urea, and the like. In addition, one or more of the above-described components may be blended according to the characteristics of the product.
- ka Coloring pigments such as yellow iron oxide, black iron oxide, red iron oxide, ultramarine, chromium oxide and chromium hydroxide can be used as extender pigments such as rhenium, nylon powder,
- the functional cosmetic composition may be prepared in any form conventionally produced in the art and may be in the form of, for example, a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant- , A powder foundation, an emulsion foundation, a wax foundation, and a spray, but is not limited thereto. More specifically, it can be manufactured in the form of a soft lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.
- the formulation is a paste, cream or gel
- an animal oil a vegetable oil, a wax, a paraffin, a starch, a tracer, a cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide
- a carrier component a carrier component that may be used as a carrier component .
- lactose When the formulation is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component.
- talc In the case of a spray, in particular, chlorofluorohydrocarbons, propane / Or propellants such as dimethyl ether.
- a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, - butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid esters of sorbitan.
- a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, a microcrystalline cellulose , Aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
- the carrier component is selected from the group consisting of aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate , Alkylamido betaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives, or ethoxylated glycerol fatty acid esters.
- the present invention also relates to a pharmaceutical composition for antiinflammation comprising the green tea extract of the present invention as an active ingredient.
- the green tea extract contains 0.1 to 50% by weight based on the total weight of the composition.
- the content is in the above range, it is not only suitable for exhibiting the intended effect of the present invention but also can satisfy both stability and safety of the composition and is preferable from the viewpoint of cost effectiveness.
- the pharmaceutical composition according to the present invention can be orally administered in the form of solid, semi-solid or liquid with addition of a compatible inorganic or organic carrier.
- a compatible inorganic or organic carrier examples include tablets, pills, soft and hard capsules, powders, fine granules, granules, solutions, emulsions, syrups and pellets.
- the pharmaceutical composition can be easily formulated according to a conventional method, and a surfactant, an excipient, a coloring agent, a spice, a preservative, a stabilizer, a buffer, a suspending agent or other commonly used adjuvant can be suitably used.
- the dosage of the active ingredient will vary depending on the age, sex, body weight and the disease or condition to be treated, the route of administration, or the judgment of the prescriber. Dosage determinations based on these factors are within the level of those skilled in the art and may be administered, for example, 100 to 1,000 mg, preferably 300 to 500 mg, in divided doses of 1 to 3 times per day, Are not intended to limit the scope of the present invention.
- the pharmaceutical composition may be administered as an individual therapeutic agent or in combination with another therapeutic agent, and may be administered sequentially or simultaneously with a conventional therapeutic agent. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without adverse effect, and can be easily determined by those skilled in the art.
- the present invention also relates to an anti-inflammatory food composition
- an anti-inflammatory food composition comprising the green tea extract of the present invention as an active ingredient.
- the green tea extract contains 0.1 to 50% by weight based on the total weight of the composition.
- the content is in the above range, it is not only suitable for exhibiting the intended effect of the present invention but also can satisfy both stability and safety of the composition and is preferable from the viewpoint of cost effectiveness.
- the food composition according to the present invention may further comprise, in addition to the above-mentioned components, other ingredients effective for preventing, ameliorating or treating obesity at a level that does not inhibit the efficacy of the green tea extract.
- other ingredients effective for preventing, ameliorating or treating obesity at a level that does not inhibit the efficacy of the green tea extract.
- the food composition according to the present invention may be a health food, a functional food, and a food additive composition.
- the composition can be applied to various formulations such as tablets, pills, capsules, granules, drinks, caramels, diet bars, and tea bags through a conventional method including adding various kinds of excipients or additives.
- the compositions may be formulated without difficulty by those of ordinary skill in the art, in addition to the active ingredients, which are conventionally used in the art, and synergistic effects may occur when combined with other ingredients.
- the complex enzyme in which the green tea extract was mixed with glucanase and Arabinanase at a weight ratio of 1: 1 was added to the green tea extract in an amount of 10% by weight based on the total weight of the green tea extract and reacted at 40 ° C for 24 hours.
- the complex enzyme was deactivated for 1 hour. Thereafter, the filtrate was concentrated by using a filter cloth to remove ethanol, and the concentrate was concentrated to contain only 10% by weight of the solid content.
- the concentrate was adsorbed on a column equipped with an adsorption resin, washed with water 2 to 5 times the column volume, eluted with 2 to 5 times of the alcohol, and concentrated and lyophilized to obtain a green tea extract Respectively.
- Flavonol, myristate, quercetin and camelol were purchased from Sigma.
- the instrument was analyzed by HPLC (Waters Alliance 2695 system, Waters, USA) and the detection wavelengths were 275 nm (catechin) and 365 nm (flavonol).
- the column was analyzed by concentration gradient solvent composition method using 0.1% formic acid (FA) and acetonitrile (ACN) solvent using Agilent Poroshell SB C18 (150 x 4.6 mm, 2.7 ⁇ m) Respectively. All analytical solvents were HPLC grade reagents and data were processed using Waters' Empower 2 program.
- the green tea extract of Example 1 prepared using the complex enzyme exhibited a higher activity than the green tea extract of Comparative Example 1, which was prepared without using the complex enzyme, as compared with the green tea extract of Galactan, non-gallate catechin and flavonol And it was confirmed that the contents were all high.
- the gallic acid was about 98 times
- the non-galactic catechin was about 2.5 times
- the Flavonol anhydride was about 7.5 times.
- the green tea extract of Comparative Example 1 contained more gallate catechins than the non-gallate catechins, but the green tea extract of Example 1 showed that most of the catechins were non-gallate catechins.
- the green tea extract of the present invention prepared using the complex enzyme increases the content of asparagine of gallic acid, non-gallate catechin and flavonol.
- the RAW 264.7 mouse-derived macrophage cell line purchased from the American Type Culture Collection (ATCC) ), Interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2)
- the RAW 264.7 cell line was cultured on a 6 well plate at a density of 1 ⁇ 10 6 / well.
- the green tea extract of Example 1 and Comparative Example 1 was pretreated for 2 hours at a concentration of 10 g / ml, and LPS (Lipopolysaccharide) 6 hrs to induce an inflammatory reaction.
- IL-1 ⁇ IL-1 ⁇
- IL-6 interleukin-6
- COX-2 cyclooxygenase
- FIGS. 1 to 3 show the result of treatment of RAW 264.7 macrophage cell line with unstimulated control, LPS as a positive control, and LPS and green tea extract of Example 1 and Comparative Example 1, respectively, 1 (IL-1?), Interleukin-6 (IL-6) and cyclooxygenase (COX-2).
- the green tea extract prepared in Comparative Example 1 inhibited the production of interleukin-1? (IL-1?), Interleukin-6 (IL-6) and cyclooxygenase (COX-2).
- the Flavonol of the flavonol was fractionated from the green tea extract.
- Flavonol fractions of flavonol were prepared by dissolving each of the green tea extracts of Example 1 in DMSO and methanol mixed solvent (1: 9, v / v) at a concentration of 20%. Thereafter, the filtrate was adsorbed on a column (35x250 mm, 10 mu m, C18), and a fraction of an unglycosylated flavonol obtained by using a concentration gradient of water and acetonitrile was concentrated and lyophilized.
- the green tea extract containing 35% of epicatechin was added to the human colon cancer cell line (HT-29).
- the experimental group was divided into three groups.
- quercetin was added as a positive control and blank fraction of flavonol of Example 1 was added to the test group in an amount of 100 ppm each for 1 hour Lt; / RTI > Then, the cells were washed with PBS, 500 ⁇ L of a mixed solution of 90% methanol and 10% DMSO was added and the cells were disrupted by sonication.
- the impurities were purified using a 0.45 ⁇ m PDVF filter, and the content of intracellular catechin Were measured.
- the green tea extract prepared by the production method of the present invention promotes absorption of intracellular catechin by increasing the content of the irregular body of flavonol.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Botany (AREA)
- Birds (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a method for preparing a green tea extract having increased content of gallic acid, non-gallate catechin, and aglycon of flavonol, and to an green tea extract prepared therefrom, and to an anti-inflammatory cosmetic, pharmaceutical and food composition containing the same.
Description
본 출원은 2017년 11월 14일자 한국 특허출원 제10-2017-0151218호에 기초한 우선권의 이익을 주장하며, 해당 한국 특허 출원의 문헌에 개시된 모든 내용을 본 명세서의 일부로서 포함한다.This application claims the benefit of priority based on Korean Patent Application No. 10-2017-0151218, filed on November 14, 2017, which is incorporated herein by reference in its entirety.
본 발명은 녹차 추출물 제조방법 및 이로부터 제조된 녹차 추출물에 관한 것으로, 보다 자세하게는 갈산, 비-갈레이트 카테킨 및 플라보놀의 비당체의 함량이 증대된 녹차 추출물 제조방법 및 이로부터 제조된 녹차 추출물에 관한 것이다.The present invention relates to a method for preparing green tea extract and a green tea extract prepared therefrom, and more particularly, to a method for preparing green tea extract having an increased amount of aspartic acid of gallic acid, non-gallate catechin and flavonol, .
차는 동백과(Theaceae), 동백속(Camellia)에 속하는 차나무(Camellia sinensis O, Kuntze)의 싹이나 잎을 가공한 것으로서 차 생엽에는 75 내지 80%의 수분과 20 내지 25%의 고형분이 함유되어 있으며, 고형분에는 카테킨, 카페인, 아미노산, 섬유소, 펙틴 등의 유기물과 지질, 수지류, 정유, 비타민, 클로로필 등 다양한 성분이 함유되어 있다. 이 성분들이 차의 독특한 맛과 풍미를 형성하며 특히 카테킨류에 의한 콜레스테롤 상승 억제, 혈당 상승 저해 작용, 동맥경화방지 작용, 항산화 작용, 항균 작용, 항궤양 작용 및 돌연변이 억제 작용 등의 생리활성 효능이 과학적으로 규명되어 보건음료 및 기능성 식품으로서의 가치가 재평가되고 있다.The tea is a sprout or leaf of Camellia sinensis O, Kuntze, which belongs to Camellia (Camellia) and contains 75-80% moisture and 20-25% solids. , Solid contents include various organic compounds such as catechin, caffeine, amino acid, fiber, and pectin, lipid, resin, essential oil, vitamin, chlorophyll and the like. These ingredients form a unique taste and flavor of tea, and particularly have physiological activity effects such as inhibition of cholesterol elevation by catechins, inhibition of blood sugar increase, inhibition of arteriosclerosis, antioxidant activity, antibacterial activity, antiulcer activity and mutation inhibition Scientifically identified, the value of health beverages and functional foods is being reassessed.
녹차에는 항산화 물질인 카테킨이 다량으로 함유되어 있으며 이는 인체에서 저밀도 지방단백질에 대한 산화억제작용과 콜레스테롤 생합성 억제작용이 높은 것으로 알려져 있다. 카테킨은 녹차에 함유되어 있는 카테킨류를 총칭하며 상기 카테킨류로는 카테킨(Catechin; C), 갈로카테킨(Gallocatechin; GC), 에피카테킨(Epicatechin; EC), 에피갈로카테킨(Epigallocatechin; EGC), 에피카테킨갈레이트(Epicatechingallate; ECG), 에피갈로카테킨갈레이트(Epigallocatechingallate; EGCG) 등이 있으며 이중에서 에피갈로카테킨갈레이트가 가장 많은 양을 차지하며 생리활성 또한 가장 높은 것으로 알려져 있다. Green tea contains a large amount of antioxidant catechin, which is known to inhibit oxidation of low density lipoproteins in the human body and to inhibit cholesterol biosynthesis. Catechin is a generic term for catechins contained in green tea and catechins such as catechin (C), gallocatechin (GC), epicatechin (EC), epigallocatechin (EGC), epicatechin Epicatechallocatechin gallate (EGCG), epigallocatechin gallate is the most abundant, and its physiological activity is also known to be the highest.
카테킨류 중에서, 갈레이트를 포함하지 않는 비(非)-갈레이트 카테킨 비율을 제어함으로써 녹차 추출물의 풍미가 개선되는 것이 알려져 있으며, 갈레이트 카테킨 비율이 높은 녹차 추출물의 효율적인 제조 기술은 알려져 있지만 비-갈레이트 카테킨 비율이 높은 녹차 추출물의 제조방법은 알려져 있지 않다.Among the catechins, it is known that the flavor of the green tea extract is improved by controlling the ratio of non-gallate catechins containing no gallate, and an efficient production technique of green tea extract having a high gallate catechin ratio is known, The production method of green tea extract having a high gallate catechin ratio is not known.
또한, 녹차 추출물의 제조에 있어 카테킨의 흡수를 돕는 물질인 미리세틴(myricetin), 퀘르세틴(Quercetin) 및 캠페롤(Kaempferol) 등의 플라보놀 비당체의 함량이 높은 녹차 추출물 제조방법에 대해서는 현재까지 보고된 바가 없다.In addition, a method for preparing green tea extract having a high content of flavonol antagonist such as myricetin, quercetin, and kaempferol, which are substances that help absorption of catechin in the production of green tea extract, There is no bar.
본 발명은 갈산, 비-갈레이트 카테킨 및 플라보놀의 비당체의 함량이 증대되어 항염 효과가 우수한 녹차 추출물 제조방법을 제공하는 것을 목적으로 한다.An object of the present invention is to provide a method for preparing green tea extract having an excellent anti-inflammatory effect by increasing the content of asparagine of gallic acid, non-galactic catechin and flavonol.
또한, 본 발명은 상기 제조방법으로 제조된 항염 효과가 우수한 녹차 추출물, 상기 추출물을 유효성분으로 포함하는 항염증용 식품 조성물, 화장료 조성물 및 약학 조성물을 제공하는 것을 목적으로 한다.It is another object of the present invention to provide a green tea extract having excellent anti-inflammatory effect and an anti-inflammatory food composition comprising the extract as an active ingredient, a cosmetic composition and a pharmaceutical composition.
상기 목적을 달성하기 위하여,In order to achieve the above object,
본 발명은 The present invention
(a)녹차 추출물을 제조하는 단계; 및(a) preparing a green tea extract; And
(b)상기 제조된 녹차 추출물 및 효소를 반응시키는 단계;를 포함하는(b) reacting the prepared green tea extract and an enzyme
갈산, 비-갈레이트 카테킨 및 플라보놀의 비당체의 함량이 증대된 녹차 추출물 제조방법으로,A method for preparing green tea extract having increased content of non-saccharide of gallic acid, non-gallate catechin and flavonol,
상기 효소는 글루카나아제 및 아라비나나아제를 포함하는 복합효소인 것을 특징으로 하는 녹차 추출물 제조방법을 제공한다.Wherein the enzyme is a complex enzyme comprising glucanase and arabinase.
또한, 본 발명은 상기 본 발명의 제조방법으로 제조된 녹차 추출물을 제공한다.The present invention also provides a green tea extract prepared by the method of the present invention.
또한, 본 발명은 상기 본 발명의 녹차 추출물을 유효성분으로 포함하는 항염증용 화장료 조성물을 제공한다.The present invention also provides an anti-inflammatory cosmetic composition comprising the green tea extract of the present invention as an active ingredient.
또한, 본 발명은 상기 본 발명의 녹차 추출물을 유효성분으로 포함하는 항염증용 약학 조성물을 제공한다.The present invention also provides a pharmaceutical composition for antiinflammation comprising the green tea extract of the present invention as an active ingredient.
또한, 본 발명은 상기 본 발명의 녹차 추출물을 유효성분으로 포함하는 항염증용 식품 조성물을 제공한다.The present invention also provides an anti-inflammatory food composition containing the green tea extract of the present invention as an active ingredient.
본 발명의 녹차 추출물 제조방법은 녹차 추출물의 갈산, 비-갈레이트 카테킨 및 플라보놀의 비당체의 함량을 증대시킬 수 있으며, 이로 인하여 우수한 항염 효과를 나타낼 수 있다.The method for preparing green tea extract of the present invention can increase the content of asparaginase of gallic acid, non-galactose catechin, and flavonol in green tea extract, and thus it can exhibit excellent anti-inflammatory effect.
또한, 본 발명의 제조방법으로 제조된 녹차 추출물은 항염 효과가 우수하여 항염증용 식품 조성물, 화장료 조성물 및 약학 조성물로 사용될 수 있다.In addition, the green tea extract prepared by the method of the present invention is excellent in anti-inflammatory effect and can be used as an anti-inflammatory food composition, a cosmetic composition and a pharmaceutical composition.
도 1은 실시예 1 및 비교예 1에서 제조한 녹차 추출물로 처리한 세포의 인터루킨-1β(IL-1β)의 mRNA 발현 정도를 측정한 그래프이다.FIG. 1 is a graph showing the degree of mRNA expression of interleukin-1? (IL-1?) In cells treated with green tea extract prepared in Example 1 and Comparative Example 1. FIG.
도 2는 실시예 1 및 비교예 1에서 제조한 녹차 추출물로 처리한 세포의 인터루킨-6(IL-6)의 mRNA 발현 정도를 측정한 그래프이다.2 is a graph showing the degree of mRNA expression of interleukin-6 (IL-6) in cells treated with green tea extract prepared in Example 1 and Comparative Example 1. FIG.
도 3은 실시예 1 및 비교예 1에서 제조한 녹차 추출물로 처리한 세포의 사이클로옥시게나아제-2(COX-2)의 mRNA 발현 정도를 측정한 그래프이다.FIG. 3 is a graph showing the degree of mRNA expression of cyclooxygenase-2 (COX-2) in cells treated with green tea extract prepared in Example 1 and Comparative Example 1. FIG.
도 4는 실시예 1에서 제조한 녹차 추출물의 세포내로 이동된 카테킨류의 함량을 측정한 그래프이다.FIG. 4 is a graph showing the content of catechins transferred into cells of the green tea extract prepared in Example 1. FIG.
이하, 본 발명을 보다 자세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명은 갈산, 비-갈레이트 카테킨 및 플라보놀의 비당체의 함량이 증대된 녹차 추출물 제조방법에 관한 것으로, The present invention relates to a method for preparing an green tea extract having increased amounts of an aspartic acid of gallic acid, non-gallate catechin and flavonol,
(a)녹차 추출물을 제조하는 단계; 및(a) preparing a green tea extract; And
(b)상기 제조된 녹차 추출물 및 효소를 반응시키는 단계;를 포함하며,(b) reacting the prepared green tea extract and an enzyme,
상기 효소는 글루카나아제 및 아라비나나아제를 포함하는 복합효소이다.The enzyme is a complex enzyme including glucanase and arabinase.
갈산(Gallic acid)은 탄닌이 가수분해되어 생성되는 물질로, 천연 항산화제로 사용되기도 하며, 비만, 항산화, 고혈압, 항균, 항염, 혈당조절, 이상지혈증 및 간기능 보호 등의 효능을 지닌 것으로 알려져 있다.Gallic acid is a substance produced by hydrolysis of tannin. It is also used as a natural antioxidant and has been known to have such effects as obesity, antioxidant, hypertension, antibacterial, anti-inflammatory, blood glucose control, dyslipidemia and liver function .
비(非)-갈레이트 카테킨(non-gallate catechin)은 플라보노이드의 일종인 카테킨류 중 갈레이트를 포함하지 않는 화합물로 항염 효과를 나타내는 것으로 알려져 있다. Non-gallate catechin is known to exhibit an anti-inflammatory effect in catechins, a type of flavonoid, which does not contain gallate.
또한, 플라보놀의 비당체는 미리세틴(myricetin), 퀘르세틴(Quercetin) 및 캠페롤(Kaempferol)을 포함하며, 상기 미리세틴, 퀘르세틴 및 캠페롤은 항산화, 항염 등의 생리활성이 뛰어나며, 카테킨의 흡수를 촉진시키는 물질로 다양한 효능이 연구되고 있으며, 다양한 분야로의 적용이 이루어지고 있다.The antiserum of flavonol includes myricetin, quercetin and kaempferol. The myristate, quercetin and camphorol have excellent physiological activities such as antioxidant and anti-inflammation, and the absorption of catechin , And various applications have been made in various fields.
상기 갈산, 비-갈레이트 카테킨 및 플라보놀의 비당체의 함량이 모두 증대된 녹차 추출물 제조방법에 대해서는 현재까지 보고된 바가 없으며, 특히 일반적인 녹차 추출물에는 거의 존재하지 않는 플라보놀의 비당체의 함량이 증대된 녹차 추출물 제조방법에 대해서는 아직 알려진 바가 없다.There has been no report on the method for preparing green tea extracts in which the content of the aspartic acid of gallic acid, non-gallate catechin and flavonol is increased. Especially, There is no known method for producing an enhanced green tea extract.
따라서, 본 발명에서는 갈산, 비-갈레이트 카테킨 및 플라보놀의 비당체의 함량이 모두 증대되어 항염 효과가 우수한 녹차 추출물 제조방법을 제공하고자 한다.Accordingly, the present invention provides a method for preparing green tea extract having an excellent anti-inflammatory effect by increasing the content of galactic acid, non-galactic catechin and an unglycoside of flavonol.
이하, 본 발명의 녹차 제조방법을 각 단계별로 설명하기로 한다.Hereinafter, the green tea producing method of the present invention will be described for each step.
상기 (a)단계는 녹차 추출물을 제조하는 단계이다.The step (a) is a step of preparing green tea extract.
본 발명에서 녹차는 통상적인 제차법으로 제조된 것일 수 있으며, 녹차는 녹차엽, 녹차줄기 및 녹차뿌리로 이루어진 군으로부터 선택되는 1종 이상을 포함할 수 있고, 바람직하게는 녹차엽을 포함할 수 있다.In the present invention, the green tea may be one prepared by a conventional ordinary method, and the green tea may include at least one selected from the group consisting of green tea leaves, green tea leaves and green tea roots, have.
또한, 녹차 추출물의 제조는 추출 용매를 사용하여 수행되며, 추출 용매는 물, 탄소수 1 내지 5의 알코올 및 초산에틸로 이루어진 군으로부터 선택되는 1종 이상을 포함하며, 바람직하게는 물 및 에탄올로 이루어진 군으로부터 선택되는 1종 이상을 포함한다.In addition, the green tea extract is prepared using an extraction solvent, and the extraction solvent includes at least one selected from the group consisting of water, an alcohol having 1 to 5 carbon atoms and ethyl acetate, and is preferably composed of water and ethanol And at least one selected from the group consisting of
또한, 추출 온도 및 추출 시간을 특별히 한정하는 것은 아니나, 바람직하게는 추출 온도는 상온 내지 80℃이며, 추출 시간은 1 내지 5시간이다.The extraction temperature and the extraction time are not particularly limited, but the extraction temperature is preferably room temperature to 80 ° C, and the extraction time is 1 to 5 hours.
상기 (a)단계의 녹차 추출물은 상기의 추출용매를 이용하여 다양한 방법을 통해 추출될 수 있다.The green tea extract of step (a) can be extracted by various methods using the above-mentioned extraction solvent.
구체적으로, 제 1 구현예로 상기 녹차 중량의 10 내지 30배수 정도의 물을 첨가하여 100℃에서 4시간 동안 1차 추출을 하고, 같은 방법으로 4시간 동안 2차 추출한 후, 1차 및 2차 추출액을 합하여 여과한 후, 여과액을 농축기로 농축한다. 상기 농축된 추출액을 분무건조 또는 진공냉동 동결 건조기를 이용하여 건조시킨다.Specifically, in the first embodiment, water of about 10 to 30 times the weight of the green tea is added and subjected to primary extraction at 100 ° C. for 4 hours, followed by secondary extraction for 4 hours in the same manner, The combined extracts are filtered, and the filtrate is concentrated with a concentrator. The concentrated extract is dried using a spray drying or vacuum freeze-freeze dryer.
제 2 구현예로 70%의 에탄올 추출물 제조방법은 녹차 중량의 10 내지 30배수 정도의 70% 에탄올을 첨가하여 50 내지 80℃에서 30분 내지 3시간 동안 추출한 후, 여과하여 여과액을 농축기로 농축한다. 상기 농축된 추출액을 분무건조 또는 진공냉동 동결 건조기를 이용하여 건조시킨다.In a second embodiment, 70% ethanol extract is prepared by adding 70% ethanol of about 10 to 30 times the weight of green tea, extracting the mixture at 50 to 80 ° C for 30 minutes to 3 hours, filtering and concentrating the filtrate with a concentrator do. The concentrated extract is dried using a spray drying or vacuum freeze-freeze dryer.
제 3 구현예로 95%의 에탄올 추출물 제조방법은 녹차 중량의 10 내지 30배수 정도의 95% 에탄올을 첨가하여 실온에서 1일 내지 3일 동안 방치(6시간 마다 shaking 작업을 반복 실시)하여 추출한 후, 같은 방법으로 2회 반복 실시하여 추출액을 얻는다. 상기 1차 및 2차 추출액을 합하여 여과한 후, 여과액을 농축기로 농축한다. 상기 농축된 추출액을 분무건조 또는 진공냉동 동결 건조기를 이용하여 건조시킨다.In a third embodiment, 95% ethanol extract is prepared by adding 95% ethanol of about 10 to 30 times the weight of green tea, allowing to stand at room temperature for 1 to 3 days (shaking operation is repeated every 6 hours) , And the same procedure is repeated twice to obtain an extract. The primary and secondary extracts are combined and filtered, and the filtrate is concentrated with a concentrator. The concentrated extract is dried using a spray drying or vacuum freeze-freeze dryer.
본 발명에서는 상기 제 2 구현예로 녹차 추출물을 제조하는 것이 가장 바람직하다.In the present invention, it is most preferable to prepare the green tea extract according to the second embodiment.
상기 (b)단계는 상기 (a)단계에서 제조된 녹차 추출물 및 효소를 반응시키는 단계이다.The step (b) is a step of reacting the green tea extract and the enzyme produced in the step (a).
상기 효소는 복합효소로, 검정곰팡이(Aspergillus niger) 유래의 글루카나아제(glucanase, enzyme code number 3.2.1.6) 및 아라비나나아제(arabinanase, enzyme code number 3.2.1.99)를 포함한다.The enzyme is a complex enzyme, and contains glucanase (enzyme code number 3.2.1.6) derived from a black mold ( Aspergillus niger ) and arabinanase (enzyme code number 3.2.1.99).
상기 복합효소는 당을 가수분해하며, 녹차 추출물에 상기 복합효소를 반응시킴으로써 녹차 추출물에 함유된 플라보놀 배당체를 가수분해 하여 플라보놀의 비당체의 함량을 증가시킬 수 있다. 또한, 녹차 추출물에 함유된 카테킨류 중 갈레이트를 포함한 카테킨류 화합물을 디갈레이트 시킴으로써 비-갈레이트 카테킨 및 갈산의 함량을 증가시킬 수 있다.The complex enzyme hydrolyzes the sugar, and by reacting the green tea extract with the complex enzyme, the flavonol glycoside contained in the green tea extract can be hydrolyzed to increase the content of the flavonol sugar. In addition, the content of non-galactose catechins and gallic acid can be increased by decalizing catechin compounds including gallate among the catechins contained in the green tea extract.
상기 복합효소는 상기 (a)단계에서 제조된 녹차 추출물 총 중량에 대하여 3 내지 30 중량%로 포함되며, 바람직하게는 5 내지 15 중량%로 포함된다.The complex enzyme is contained in an amount of 3 to 30% by weight, preferably 5 to 15% by weight based on the total weight of the green tea extract prepared in the step (a).
상기 복합효소가 3 내지 30 중량%로 포함되면 공정상 적합한 가수분해 시간을 얻을 수 있다.When the complex enzyme is contained in an amount of 3 to 30% by weight, an appropriate hydrolysis time can be obtained in the process.
또한, 상기 복합효소는 글루카나아제 및 아라비나나아제를 1:10 내지 10:1의 중량비로 포함하며, 바람직하게는 1:5 내지 5:1의 중량비로 포함한다.In addition, the complex enzyme comprises glucanase and arabinanase in a weight ratio of 1:10 to 10: 1, preferably in a weight ratio of 1: 5 to 5: 1.
상기 글루카나아제 및 아라비나나아제를 1:10 내지 10:1의 중량비로 포함하면 효소반응 시간 내에 플라보놀 배당체의 당과 카테킨의 갈레이트를 동시에 일정량 이상 가수분해 할 수 있다.When the glucanase and arabinanase are contained at a weight ratio of 1:10 to 10: 1, the sugar of the flavonol glycoside and gallate of the catechin can be simultaneously hydrolyzed by more than a predetermined amount during the enzyme reaction time.
또한, 상기 녹차 추출물 및 복합효소는 20 내지 60℃에서 12 내지 48시간 동안 반응이 수행될 수 있으며, 바람직하게는 30 내지 50℃에서 20 내지 30시간 동안 수행될 수 있다.The green tea extract and the complex enzyme may be reacted at 20 to 60 ° C for 12 to 48 hours, preferably 30 to 50 ° C for 20 to 30 hours.
상기 녹차 추출물 및 복합효소는 20 내지 60℃에서 12 내지 48시간 동안 반응이 수행됨에 따라 플라보놀에 결합된 당을 가수분해할 수 있으며 동시에 카테킨의 갈레이트를 가수분해 할 수 있어 플라보놀의 비당체 및 비-갈레이트 카테킨의 함량을 증대시킬 수 있다. 그러나 상기 온도 범위를 벗어나면 복합효소가 제대로 작용하지 못하거나 실활될 수 있다. 또한, 상기 반응 시간 이내에서는 가수분해가 충분하게 이루어져 플라보놀의 비당체 및 비-갈레이트 카테킨의 함량을 증대시킬 수 있으나, 반응 시간 이후에는 카테킨류가 산화되어 비-갈레이트 카테킨의 함량이 감소할 수 있다.The green tea extract and the complex enzyme can hydrolyze the sugar bound to flavonol and hydrolyze the gallate of catechin as the reaction is carried out at 20 to 60 ° C for 12 to 48 hours, And the content of non-galactose catechins can be increased. However, if the temperature range is exceeded, the complex enzyme may not function properly or may be inactivated. Also, the hydrolysis is sufficient within the reaction time to increase the content of flavonol aspartate and non-galactate catechin. However, after the reaction time, the catechins are oxidized to decrease the content of non-galactose catechin can do.
또한, 본 발명은 상기 녹차 추출물 및 복합효소를 반응시킨 후 상기 복합효소를 실활시키는 단계를 추가로 포함할 수 있다. 상기 실활은 50 내지 90℃에서 10분 내지 3시간 동안 수행될 수 있으며, 바람직하게는 65 내지 80℃에서 30분 내지 1시간 동안 수행될 수 있다.In addition, the present invention may further include the step of inactivating the complex enzyme after reacting the green tea extract and the complex enzyme. The deactivation may be performed at 50 to 90 ° C for 10 minutes to 3 hours, preferably at 65 to 80 ° C for 30 minutes to 1 hour.
상기 실활이 50 내지 90℃에서 10분 내지 3시간 동안 수행됨에 따라 플라보놀 및 카테킨의 손실을 줄이고 효소작용을 중지시킬 수 있다. 그러나 상기 온도 및 시간 미만에서는 효소가 실활되지 않으며, 상기 온도 및 시간을 초과하면 카테킨의 손실이 매우 크다.As the inactivation is carried out at 50 to 90 캜 for 10 minutes to 3 hours, loss of flavonol and catechin can be reduced and enzyme action can be stopped. However, the enzyme is not inactivated below the temperature and time, and when the temperature and time are exceeded, the loss of the catechin is very large.
또한, 본 발명은 상기 (b)단계에서 제조된 녹차 추출물의 당을 제거하는 단계를 추가로 포함할 수 있다. In addition, the present invention may further include a step of removing sugar from the green tea extract prepared in the step (b).
구체적으로, 상기 (b)단계에서 제조된 녹차 추출물을 농축하여 농축액을 제조한 뒤, 상기 농축액으로부터 당을 제거하는 단계를 추가로 포함할 수 있다.Specifically, the method may further include a step of concentrating the green tea extract prepared in step (b) to prepare a concentrate, and then removing sugar from the concentrate.
상기 녹차 추출물 및 복합효소를 반응시킨 후 여과하여 여과액을 농축기로 농축하여 농축액을 제조한다. 이 때 상기 농축액은 고형분을 약 10 중량%로 포함하는 것이 바람직하다.The green tea extract and the complex enzyme are reacted and then filtered to concentrate the filtrate with a concentrator to prepare a concentrate. At this time, it is preferable that the concentrated liquid contains about 10% by weight of solids.
상기 당의 제거는 그 방법을 특별히 한정하는 것은 아니나, 본 발명에서는 크로마토그래피를 이용하여 당을 분리하여 제거하는 것이 바람직하다.Although the method of removing the sugar is not particularly limited, in the present invention, it is preferable to separate and remove sugar using chromatography.
일 구현예로, 상기 제조된 농축액을 흡착레진이 장착된 컬럼에 흡착시키고, 컬럼 부피의 2 내지 5배의 물로 수세한 뒤, 2 내지 5배의 주정으로 용리하여 녹차 분획액을 얻을 수 있다.In one embodiment, the concentrate is adsorbed on a column equipped with an adsorption resin, and is washed with water 2 to 5 times the column volume and eluted with 2 to 5 times of the alcohol to obtain a green tea fraction.
상기 분획액을 농축 및 동결건조하여 녹차 추출물을 제조할 수 있으며, 상기 동결건조는 그 방법을 특별히 한정하지는 않으며, 당 업계에서 공지된 방법으로 이루어질 수 있다.The fraction may be concentrated and lyophilized to prepare a green tea extract. The lyophilization method is not particularly limited, and may be performed by a method known in the art.
상기 본 발명의 녹차 추출물 제조방법은 갈산, 비-갈레이트 카테킨 및 플라보놀의 비당체의 함량이 증대된 녹차 추출물 제조방법을 제공할 수 있으며, 그 중에서도 플라보놀의 비당체의 함량이 매우 증대된 제조방법을 제공할 수 있다.The method for preparing green tea extract of the present invention can provide a method for preparing green tea extract having increased content of asparaginase of gallic acid, non-gallate catechin and flavonol. Among them, A manufacturing method can be provided.
상기 비-갈레이트 카테킨은 카테킨류 중 갈레이트를 포함하지 않는 카테킨을 뜻하는 것으로, 상기 비-갈레이트 카테킨은 갈로카테킨, 에피갈로카테킨, 카테킨 및 에피카테킨을 포함한다.The non-galactose catechins refer to catechins not containing galate among catechins, and the non-gallyate catechins include gallocatechin, epigallocatechin, catechin, and epicatechin.
또한, 상기 플라보놀의 비당체는 미리세틴, 퀘르세틴 및 캠페롤을 포함한다.In addition, the antiserum of flavonol includes prednisine, quercetin and camphorol.
상기 녹차 추출물은 녹차 추출물 총 중량에 대하여 갈산 2 내지 10 중량% 및 비-갈레이트 카테킨 20 내지 60 중량%로 포함하며, 플라보놀의 비당체를 4 내지 15mg/g로 포함한다.The green tea extract contains 2 to 10% by weight of gallic acid and 20 to 60% by weight of non-gallate catechin based on the total weight of the green tea extract, and contains 4 to 15 mg / g of irregular body of flavonol.
또한, 비-갈레이트 카테킨은 카테킨류 총 중량에 대하여 70 내지 100 중량%로 포함된다.In addition, the non-galactose catechins are included in an amount of 70 to 100% by weight based on the total weight of the catechins.
상기 갈산, 비-갈레이트 카테킨 및 플라보놀의 비당체는 항염 효과를 지니고 있다. 따라서, 본 발명에서 상기 녹차 추출물의 갈산, 비-갈레이트 카테킨 및 플라보놀의 비당체의 함량을 모두 증대시킴으로써 항염 효과를 나타낼 수 있다. 또한, 상기 플라보놀의 비당체는 카테킨류의 흡수를 촉진시켜주는 역할을 하므로 플라보놀의 비당체의 함량이 증대되면 항염 효과를 보다 극대화시킬 수 있다.The glycans, the non-galactose catechins and the antigens of flavonols have anti-inflammatory effects. Therefore, in the present invention, the anti-inflammatory effect can be exhibited by increasing the content of galactic acid, non-galactose catechin, and flavonol in the green tea extract. In addition, since the irregular body of the flavonol promotes the absorption of catechins, the anti-inflammatory effect can be maximized by increasing the content of the irreversible body of flavonol.
보다 자세하게는 인터루킨-1β(IL-1β), 인터루킨-6(IL-6) 및 사이클로옥시게나아제-2(COX-2)로 이루어진 군으로부터 선택되는 1종 이상의 발현을 억제하는 활성을 통하여 항염 효과를 나타낼 수 있다.(IL-1), interleukin-6 (IL-6) and cyclooxygenase-2 (COX-2) Lt; / RTI >
또한, 본 발명은 상기 본 발명의 제조방법으로 제조된 녹차 추출물에 관한 것이다.The present invention also relates to green tea extract prepared by the production method of the present invention.
상기 본 발명의 녹차 추출물은 종래의 녹차 추출물 보다 갈산, 비-갈레이트 카테킨 및 플라보놀의 비당체의 함량이 높으며, 특히 플라보놀의 비당체의 함량이 종래의 녹차 추출물 보다 높다. The green tea extract of the present invention has higher content of non-saccharides of gallic acid, non-galactic catechin and flavonol than that of the conventional green tea extract. Especially, the content of fly ash is higher than that of the conventional green tea extract.
구체적으로, 녹차 추출물 총 중량에 대하여 갈산 2 내지 10 중량% 및 비-갈레이트 카테킨 20 내지 60 중량%로 포함하며, 플라보놀의 비당체를 4 내지 15mg/g로 포함한다.Specifically, it contains 2 to 10% by weight of gallic acid and 20 to 60% by weight of non-gallate catechin based on the total weight of the green tea extract, and contains 4 to 15 mg / g of irregular body of flavonol.
또한, 본 발명의 녹차 추출물은 인터루킨-1β(IL-1β), 인터루킨-6(IL-6) 및 사이클로옥시게나아제-2(COX-2)로 이루어진 군으로부터 선택되는 1종 이상의 발현을 억제하는 활성을 통하여 항염 효과를 나타낼 수 있다.In addition, the green tea extract of the present invention inhibits the expression of at least one selected from the group consisting of interleukin-1? (IL-1?), Interleukin-6 (IL-6) and cyclooxygenase- Activity can be exhibited.
따라서, 상술한 바와 같이 본 발명의 녹차 추출물은 항염 효과를 나타낼 수 있다.Therefore, as described above, the green tea extract of the present invention can exhibit anti-inflammatory effect.
또한, 본 발명은 상기 본 발명의 녹차 추출물을 유효성분으로 포함하는 항염증용 화장료 조성물에 관한 것이다.The present invention also relates to an anti-inflammatory cosmetic composition containing the green tea extract of the present invention as an active ingredient.
상기 항염증용 화장료 조성물은 기능성 화장품의 유효성분으로 사용될 수 있는데, 상기 기능성 화장품에 포함되는 상기 녹차 추출물의 함량은 특별히 제한되지 않으나 일 예로서, 0.01 내지 99.9 중량%가 될 수 있다.The cosmetic composition for anti-inflammation may be used as an active ingredient of functional cosmetics. The content of the green tea extract contained in the functional cosmetics is not particularly limited, and may be, for example, 0.01 to 99.9% by weight.
본 발명의 기능성 화장품은 상기 녹차 추출물을 유효성분으로 포함하고, 통상적으로 사용되는 화장료를 추가로 포함할 수 있는데, 예를 들면 수용성 스킨제제화를 위하여 글리세롤, 프로필렌글리콜, 1,3-부틸렌글리콜, 솔비톨, 폴리에틸렌글리콜, 카르복시비닐 폴리머, 잔탄검, 카르복시메틸셀룰로오스, 하이드록시에틸셀룰로오스, 하이드록시메틸셀룰로오스, 로커스트빈검, 알란토인, 카라기난 등을 첨가할 수 있으며, 점도와 경도조절제로 밀납, 파라핀 왁스, 스테아릴알콜, 카르나우바 왁스, 칸데릴라 왁스 및 칼슘스테아레이트, 알루미늄스테아레이트, 아연스테아레이트, 위치하젤(witchhazel) 등을 사용할 수 있고, 자외선 흡수제로 부틸메톡시디벤조일메탄, 옥틸메톡시신나메이트 등을 사용할 수 있으며, 안료로는 이산화티탄, 미립자 이산화디탄, 카올린, 나이론 파우다, 탈크, 세리사이트, 마이카, 폴리메틸메타크릴레이트 등의 체질 안료와 황색산화철, 흑색산화철, 적색산화철, 울트라마린, 산화크롬, 수산화크롬 등의 착색안료를 사용할 수 있고, 보습제로 1,3-부틸렌글리콜, 농글리세린, 에틸렌글리콜 등과 키틴, 키토산, 히아론산, 하이알루로닌산, 젖산, 글리콜산 등의 천연보습 물질들을 이용할 수 있으며, 방부제로 파라옥시안식향산 에스테르류, 이미다졸리디닐우레아 등을 사용할 수 있을 뿐만 아니라, 상기한 성분들을 제품특성에 따라 1종 또는 2종이상 혼용 배합할 수도 있다.The functional cosmetic of the present invention may further comprise cosmetics conventionally used as an active ingredient of the green tea extract. For example, glycerol, propylene glycol, 1,3-butylene glycol, It is possible to add a surfactant such as sorbitol, polyethylene glycol, carboxyvinyl polymer, xanthan gum, carboxymethylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, locust bean gum, allantoin, carrageenan, Aluminum stearate, zinc stearate, and witchhazel can be used. As the ultraviolet absorber, butylmethoxydibenzoylmethane, octylmethoxycinnamate, etc. may be used. As the pigment, there can be used titanium dioxide, particulate ditanium dioxide, ka Coloring pigments such as yellow iron oxide, black iron oxide, red iron oxide, ultramarine, chromium oxide and chromium hydroxide can be used as extender pigments such as rhenium, nylon powder, talc, sericite, mica and polymethyl methacrylate, Natural moisturizing substances such as chitin, chitosan, hyaluronic acid, hyaluronic acid, lactic acid, glycolic acid and the like can be used, and as a preservative, paraoxybenzoic acid esters, imida Zoledinyl urea, and the like. In addition, one or more of the above-described components may be blended according to the characteristics of the product.
상기 기능성 화장품은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징폼, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The functional cosmetic composition may be prepared in any form conventionally produced in the art and may be in the form of, for example, a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant- , A powder foundation, an emulsion foundation, a wax foundation, and a spray, but is not limited thereto. More specifically, it can be manufactured in the form of a soft lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.
상기 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation is a paste, cream or gel, an animal oil, a vegetable oil, a wax, a paraffin, a starch, a tracer, a cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component .
상기 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, chlorofluorohydrocarbons, propane / Or propellants such as dimethyl ether.
상기 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산에스테르가 있다.When the formulation is a solution or an emulsion, a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, - butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid esters of sorbitan.
상기 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡 실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, a microcrystalline cellulose , Aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
상기 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation is an interface-active agent-containing cleansing, the carrier component is selected from the group consisting of aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate , Alkylamido betaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives, or ethoxylated glycerol fatty acid esters.
또한, 본 발명은 본 발명의 녹차 추출물을 유효성분으로 포함하는 항염증용 약학 조성물에 관한 것이다.The present invention also relates to a pharmaceutical composition for antiinflammation comprising the green tea extract of the present invention as an active ingredient.
본 발명에 따르면 상기 녹차 추출물은 상기 조성물 총 중량 대비 0.1 내지 50 중량%로 포함한다. 상기 함량일 경우 본 발명의 의도한 효과를 나타내기에 적절할 뿐만 아니라, 조성물의 안정성 및 안전성을 모두 만족할 수 있으며, 비용 대비 효과의 측면에서도 바람직하다.According to the present invention, the green tea extract contains 0.1 to 50% by weight based on the total weight of the composition. When the content is in the above range, it is not only suitable for exhibiting the intended effect of the present invention but also can satisfy both stability and safety of the composition and is preferable from the viewpoint of cost effectiveness.
본 발명에 따른 약학 조성물은, 상용되는 무기 또는 유기의 담체를 가하여 고체, 반고체 또는 액상의 형태로 경구 투여할 수 있다. 상기 경구 투여를 위한 제재로서는 정제, 환제, 연질 및 경질 캡슐제, 산제, 세립제, 과립제, 용액, 유탁제, 시럽제 및 펠렛제 등을 들 수 있다.The pharmaceutical composition according to the present invention can be orally administered in the form of solid, semi-solid or liquid with addition of a compatible inorganic or organic carrier. Examples of the agent for oral administration include tablets, pills, soft and hard capsules, powders, fine granules, granules, solutions, emulsions, syrups and pellets.
상기 약학 조성물은 상법에 따라서 용이하게 제제화할 수 있으며, 계면 활성제, 부형제, 착색료, 향신료, 보존료, 안정제, 완충제, 현탁제 또는 기타 상용하는 보조제를 적당히 사용할 수 있다.The pharmaceutical composition can be easily formulated according to a conventional method, and a surfactant, an excipient, a coloring agent, a spice, a preservative, a stabilizer, a buffer, a suspending agent or other commonly used adjuvant can be suitably used.
또한, 상기 유효 성분의 투여량은 치료받을 대상의 연령, 성별, 체중 및 치료할 질환 또는 병리 상태, 투여 경로 또는 처방자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 투여량 결정은 당업자의 수준 내에 있고, 예를 들어 100 내지 1,000mg, 바람직하게는 300 내지 500 mg 을 1일 1 내지 3회 분할하여 투여할 수 있으나, 상기 투여량은 어떠한 방법으로도 본 발명의 범위를 한정하는 것이 아니다.In addition, the dosage of the active ingredient will vary depending on the age, sex, body weight and the disease or condition to be treated, the route of administration, or the judgment of the prescriber. Dosage determinations based on these factors are within the level of those skilled in the art and may be administered, for example, 100 to 1,000 mg, preferably 300 to 500 mg, in divided doses of 1 to 3 times per day, Are not intended to limit the scope of the present invention.
상기 약학 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여될 수 있다. 상기 요소를 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 당업자에 의해 용이하게 결정될 수 있다.The pharmaceutical composition may be administered as an individual therapeutic agent or in combination with another therapeutic agent, and may be administered sequentially or simultaneously with a conventional therapeutic agent. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without adverse effect, and can be easily determined by those skilled in the art.
또한, 본 발명은 본 발명의 녹차 추출물을 유효성분으로 포함하는 항염증용 식품 조성물에 관한 것이다.The present invention also relates to an anti-inflammatory food composition comprising the green tea extract of the present invention as an active ingredient.
본 발명에 따르면 상기 녹차 추출물은 상기 조성물 총 중량에 대하여 0.1 내지 50 중량%로 포함한다. 상기 함량일 경우 본 발명의 의도한 효과를 나타내기에 적절할 뿐만 아니라, 조성물의 안정성 및 안전성을 모두 만족할 수 있으며, 비용 대비 효과의 측면에서도 바람직하다.According to the present invention, the green tea extract contains 0.1 to 50% by weight based on the total weight of the composition. When the content is in the above range, it is not only suitable for exhibiting the intended effect of the present invention but also can satisfy both stability and safety of the composition and is preferable from the viewpoint of cost effectiveness.
본 발명에 따른 식품 조성물은 상술한 성분 이외에도 비만의 예방, 개선 또는 치료에 효과가 있는 이외의 성분을 녹차 추출물의 효능을 저해하지 않는 수준의 양에서 추가적으로 더욱 포함할 수 있다. 예컨대 당분, 산, 당알코올 중 어느 하나 이상을 포함할 수 있다.The food composition according to the present invention may further comprise, in addition to the above-mentioned components, other ingredients effective for preventing, ameliorating or treating obesity at a level that does not inhibit the efficacy of the green tea extract. For example, at least one of sugar, acid, and sugar alcohol.
본 발명에 따른 식품 조성물은 건강 식품, 기능성 식품 및 식품 첨가제 조성물일 수 있다. 상기 조성물은 다양한 종류의 부형제 또는 첨가제를 가하는 단계를 포함하는 통상적인 방법을 통하여 정제, 환제, 캅셀제, 과립제, 드링크제, 캐러멜, 다이어트바, 티백 등의 여러 제형으로 응용이 가능하다. 조성물에는 제형 또는 사용 목적에 따라 유효 성분 이외에 해당 분야에서 통상적으로 사용되는 성분들을 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 다른 성분과 배합할 경우 상승 효과가 일어날 수 있다.The food composition according to the present invention may be a health food, a functional food, and a food additive composition. The composition can be applied to various formulations such as tablets, pills, capsules, granules, drinks, caramels, diet bars, and tea bags through a conventional method including adding various kinds of excipients or additives. Depending on the formulation or purpose of use, the compositions may be formulated without difficulty by those of ordinary skill in the art, in addition to the active ingredients, which are conventionally used in the art, and synergistic effects may occur when combined with other ingredients.
이하, 본 발명을 구체적으로 설명하기 위해 실시예를 들어 상세하게 설명하기로 한다. 그러나 본 발명에 따른 실시예는 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 아래에서 상술하는 실시예에 한정되는 것으로 해석되어서는 아니 된다. 본 발명의 실시예는 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해서 제공되는 것이다.BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the present invention will be described in detail with reference to examples. However, the embodiments according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the embodiments described below. The embodiments of the present invention are provided to enable those skilled in the art to more fully understand the present invention.
<녹차 추출물 제조><Preparation of green tea extract>
실시예 1.Example 1.
건조 녹차 100g 및 70%의 에탄올을 1.5kg을 혼합하고, 60℃에서 2시간 동안 추출하였다. 그 후, 10μm 이하의 크기를 여과할 수 있는 여과지로 여과한 후, 여과액을 농축하고 분무건조하여 녹차 추출물을 제조하였다.100 g of dried green tea and 1.5 kg of 70% ethanol were mixed and extracted at 60 캜 for 2 hours. Thereafter, the solution was filtered with a filter paper having a size of 10 μm or less, and the filtrate was concentrated and spray-dried to prepare green tea extract.
상기 녹차 추출물에 글루카나아제 및 아라비나나아제가 1:1의 중량비로 혼합된 복합효소를 녹차 추출물 총 중량의 10 중량%를 첨가하여 40℃에서 24시간 동안 반응시켰으며, 80℃에서 30분 내지 1시간 동안 복합효소를 실활시켰다. 그 후, 여과포를 이용하여 여액을 농축하여 에탄올을 제거하고, 고형분의 10 중량%만 포함될 수 있도록 농축하여 농축액을 제조하였다.The complex enzyme in which the green tea extract was mixed with glucanase and Arabinanase at a weight ratio of 1: 1 was added to the green tea extract in an amount of 10% by weight based on the total weight of the green tea extract and reacted at 40 ° C for 24 hours. The complex enzyme was deactivated for 1 hour. Thereafter, the filtrate was concentrated by using a filter cloth to remove ethanol, and the concentrate was concentrated to contain only 10% by weight of the solid content.
상기 농축액을 흡착레진이 장착된 컬럼에 흡착시키고, 컬럼 부피의 2 내지 5배의 물로 수세한 뒤, 2 내지 5배의 주정으로 용리하여 얻어진 분획액을 농축 및 동결건조하여 최종적으로 녹차 추출물을 제조하였다.The concentrate was adsorbed on a column equipped with an adsorption resin, washed with water 2 to 5 times the column volume, eluted with 2 to 5 times of the alcohol, and concentrated and lyophilized to obtain a green tea extract Respectively.
비교예 1.Comparative Example 1
건조 녹차 100g 및 70%의 에탄올을 1.5kg을 혼합하고, 60℃에서 2시간 동안 추출하였다. 그 후, 10μm 이하의 크기를 여과할 수 있는 여과지로 여과한 후, 여과액을 농축하고 분무건조하여 녹차 추출물을 제조하였다.100 g of dried green tea and 1.5 kg of 70% ethanol were mixed and extracted at 60 캜 for 2 hours. Thereafter, the solution was filtered with a filter paper having a size of 10 μm or less, and the filtrate was concentrated and spray-dried to prepare green tea extract.
상기 녹차 추출물에 물을 첨가하여 10%(w/v) 용액을 제조한 뒤, 상기 용액을 흡착레진이 장착된 컬럼에 흡착시키고, 컬럼 부피의 2 내지 5배의 물로 수세한 뒤, 2 내지 5배의 주정으로 용리하여 얻어진 분획액을 농축 및 동결건조하여 최종적으로 녹차 추출물을 제조하였다.After adding the water to the green tea extract to prepare a 10% (w / v) solution, the solution was adsorbed onto the column equipped with the adsorption resin, washed with water 2 to 5 times the column volume, The fraction obtained by elution with a pear juice was concentrated and lyophilized to finally prepare a green tea extract.
실험예 1. 녹차 추출물의 갈산, 비-갈레이트 카테킨 및 플라보놀의 비당체 함량 측정Experimental Example 1. Measurement of non-saccharide content of gallic acid, non-galactose catechin and flavonol in green tea extract
HPLC(high performance liquid chromatography)를 사용하여 상기 실시예 1 및 비교예 1에서 제조한 녹차 추출물의 갈산, 비-갈레이트 카테킨 및 플라보놀의 비당체(미리세틴, 퀘르세틴 및 캠페롤)의 함량을 측정하였으며, 결과를 하기 표 2에 나타내었다.The content of gallic acid, non-galactose catechin and flavonol asparaginase (myrcetin, quercetin and camphorol) in the green tea extract prepared in Example 1 and Comparative Example 1 was measured using HPLC (high performance liquid chromatography) The results are shown in Table 2 below.
HPLC의 측정 조건은 하기와 같다.The measurement conditions of HPLC are as follows.
플라보놀의 비당체인 미리세틴, 퀘르세틴 및 캠페롤 표준품은 Sigma사에서 구입하였으며, 시료는 10:30:60(v/v)=DMSO:증류수:메탄올 용매에 용해하여 초음파 추출 후 0.45㎛ PVDF filter에 여과하여 기기에 주입하였다. The fragments of Flavonol, myristate, quercetin and camelol were purchased from Sigma. The samples were dissolved in distilled water: methanol solvent at 10:30:60 (v / v) = DMSO and ultrasonically extracted. Filtered and injected into the instrument.
기기는 HPLC(Waters Alliance 2695 system, Waters, USA)를 사용하였으며, 검출파장은 275nm(카테킨), 365nm(플라보놀) 영역에서 분석하였다. 컬럼은 Agilent Poroshell SB C18 (150 x 4.6 mm, 2.7μm)을 사용하여, 0.1 % Formic acid(FA)와 Acetonitrile(ACN) 용매를 사용한 농도구배용매 조성법으로 분석하였으며, 용매의 농도조성비를 하기 표 1에 나타내었다. 모든 분석용매는 HPLC급 시약을 사용하였으며, 데이터 처리는 워터스사의 Empower 2 프로그램을 사용하였다.The instrument was analyzed by HPLC (Waters Alliance 2695 system, Waters, USA) and the detection wavelengths were 275 nm (catechin) and 365 nm (flavonol). The column was analyzed by concentration gradient solvent composition method using 0.1% formic acid (FA) and acetonitrile (ACN) solvent using Agilent Poroshell SB C18 (150 x 4.6 mm, 2.7 μm) Respectively. All analytical solvents were HPLC grade reagents and data were processed using Waters' Empower 2 program.
| Time(min)Time (min) | Flow(mL/min)Flow (mL / min) | %A% A | %B% B | curvecurve |
| 0.000.00 | 0.80.8 | 9292 | 88 | 66 |
| 22 | 0.80.8 | 9292 | 88 | 66 |
| 33 | 0.80.8 | 8888 | 1212 | 66 |
| 44 | 0.80.8 | 8484 | 1616 | 66 |
| 1212 | 0.80.8 | 8484 | 1616 | 66 |
| 1515 | 0.80.8 | 8080 | 2020 | 66 |
| 1818 | 0.80.8 | 8080 | 2020 | 66 |
| 2121 | 0.80.8 | 7676 | 2424 | 66 |
| 2222 | 0.80.8 | 7070 | 3030 | 66 |
| 2626 | 0.80.8 | 7070 | 3030 | 66 |
| 2828 | 0.80.8 | 5050 | 5050 | 66 |
| 3030 | 0.80.8 | 5050 | 5050 | 66 |
| 3232 | 0.80.8 | 2020 | 8080 | 66 |
| 3333 | 0.80.8 | 2020 | 8080 | 66 |
| 3434 | 0.80.8 | 9292 | 88 | 66 |
| 3535 | 0.80.8 | 9292 | 88 | 66 |
% A : 0.1 % Formic acid (FA)% A: 0.1% Formic acid (FA)
% B : Acetonitrile (ACN)% B: Acetonitrile (ACN)
| 갈산(%)Gallic acid (%) | 카테킨류(%)Catechins (%) | 플라보놀의 비당체(mg/g)Fructooligosaccharide (mg / g) | |||||
| 비-갈레이트 카테킨Non-galactose catechin | 갈레이트 카테킨Gallate catechin | 미리세틴Myrrh | 퀘르세틴Quercetin | 캠페롤Camphor roll | 총합total | ||
| 실시예 1Example 1 | 5.915.91 | 40.540.5 | 0.70.7 | 3.43.4 | 5.85.8 | 3.73.7 | 12.812.8 |
| 비교예 1Comparative Example 1 | 0.060.06 | 16.516.5 | 22.222.2 | 1.11.1 | 0.30.3 | 0.30.3 | 1.71.7 |
상기 표 1의 결과에서, 복합효소를 사용하여 제조된 실시예 1의 녹차 추출물은 복합효소를 사용하지 않고 제조된 비교예 1의 녹차 추출물 보다 갈산, 비-갈레이트 카테킨 및 플라보놀의 비당체의 함량이 모두 높은 것을 확인 할 수 있었다.In the results of the above Table 1, the green tea extract of Example 1 prepared using the complex enzyme exhibited a higher activity than the green tea extract of Comparative Example 1, which was prepared without using the complex enzyme, as compared with the green tea extract of Galactan, non-gallate catechin and flavonol And it was confirmed that the contents were all high.
구체적으로 갈산이 약 98배, 비-갈레이트 카테킨이 약 2.5배, 플라보놀의 비당체가 약 7.5배 정도 증대된 것을 확인할 수 있었다.Specifically, it was confirmed that the gallic acid was about 98 times, the non-galactic catechin was about 2.5 times, and the Flavonol anhydride was about 7.5 times.
특히, 비교예 1의 녹차 추출물은 비-갈레이트 카테킨 보다 갈레이트 카테킨을 보다 많이 포함하고 있었으나, 실시예 1의 녹차 추출물은 카테킨류의 대부분이 비-갈레이트 카테킨인 것을 알 수 있었다.In particular, the green tea extract of Comparative Example 1 contained more gallate catechins than the non-gallate catechins, but the green tea extract of Example 1 showed that most of the catechins were non-gallate catechins.
따라서, 복합효소를 사용하여 제조된 본 발명의 녹차 추출물은 갈산, 비-갈레이트 카테킨 및 플라보놀의 비당체의 함량을 증대시킨다는 것을 알 수 있다.Thus, it can be seen that the green tea extract of the present invention prepared using the complex enzyme increases the content of asparagine of gallic acid, non-gallate catechin and flavonol.
실험예 2. 항염 효과 측정Experimental Example 2. Measurement of anti-inflammatory effect
상기 실시예 1 및 비교예 1에서 제조된 녹차 추출물의 항염 효과를 측정하기 위하여, American Type Culture Collection(ATCC)에서 구입한 RAW 264.7 생쥐 유래 대식세포주에서 염증 반응 관련 유전자(인터루킨-1β(IL-1β), 인터루킨-6(IL-6) 및 사이클로옥시게나아제-2(COX-2))의 mRNA 발현을 관찰하였다. In order to measure the anti-inflammatory effect of the green tea extract prepared in Example 1 and Comparative Example 1, the RAW 264.7 mouse-derived macrophage cell line purchased from the American Type Culture Collection (ATCC) ), Interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2)
RAW 264.7 세포주를 6 well-plate에 1Х106/well 밀도로 배양한 후, 실시예 1 및 비교예 1의 녹차 추출물을 10g/ml 농도로 2시간 전처리한 후 LPS(Lipopolysaccharide)를 10ng/ml 농도로 6시간 처리하여 염증 반응을 유발하였다. The RAW 264.7 cell line was cultured on a 6 well plate at a density of 1 × 10 6 / well. The green tea extract of Example 1 and Comparative Example 1 was pretreated for 2 hours at a concentration of 10 g / ml, and LPS (Lipopolysaccharide) 6 hrs to induce an inflammatory reaction.
세포를 수거하여 Trizol Reagent를 이용하여 RNA를 분리하고, RevertAid 1st strand cDNA synthesis kit을 이용하여 cDNA를 합성한 이후에 Q-PCR을 통하여 인터루킨-1β(IL-1β), 인터루킨-6(IL-6) 및 사이클로옥시게나아제(COX-2)의 mRNA 발현 정도를 관찰하였다.Cells were harvested, and RNA was isolated using Trizol Reagent. After cDNA synthesis using RevertAid 1 st strand cDNA synthesis kit, IL-1β (IL-1β), interleukin-6 (IL- 6) and cyclooxygenase (COX-2) were observed.
도 1 내지 3은 RAW 264.7 대식세포주에 무자극 대조군(control), 양성 대조군으로 LPS, 및 실험군으로 실시예 1 및 비교예 1의 LPS와 녹차 추출물을 각각 처리한 후, Q-PCR을 통하여 인터루킨-1β(IL-1β), 인터루킨-6(IL-6) 및 사이클로옥시게나아제(COX-2)의 mRNA 발현을 측정한 결과 그래프이다.FIGS. 1 to 3 show the result of treatment of RAW 264.7 macrophage cell line with unstimulated control, LPS as a positive control, and LPS and green tea extract of Example 1 and Comparative Example 1, respectively, 1 (IL-1?), Interleukin-6 (IL-6) and cyclooxygenase (COX-2).
도 1 내지 3의 결과에서, LPS만 처리한 양성대조군은 LPS를 처리하지 않은 무자극 대조군(control)에 비해 인터루킨-1β(IL-1β), 인터루킨-6(IL-6) 및 사이클로옥시게나아제(COX-2)의 생성이 증가되었음을 확인할 수 있고, LPS에 의해 증가된 인터루킨-1β(IL-1β), 인터루킨-6(IL-6) 및 사이클로옥시게나아제(COX-2)의 생성은 실시예 1로부터 제조된 녹차 추출물에 의하여 억제되는 것을 확인할 수 있다.In the results of FIGS. 1 to 3, the positive control treated with LPS alone was significantly lower than that of untreated control (control) with no LPS treatment, compared with IL-1? (IL-1?), Interleukin- (IL-1β), interleukin-6 (IL-6), and cyclooxygenase (COX-2) were increased by LPS It can be confirmed that it is inhibited by the green tea extract prepared in Example 1.
반면, 비교예 1에서 제조한 녹차 추출물은 인터루킨-1β(IL-1β), 인터루킨-6(IL-6) 및 사이클로옥시게나아제(COX-2) 생성의 억제가 미미하였다.On the other hand, the green tea extract prepared in Comparative Example 1 inhibited the production of interleukin-1? (IL-1?), Interleukin-6 (IL-6) and cyclooxygenase (COX-2).
상기 결과로부터, 본 발명의 제조방법으로 제조된 실시예 1의 녹차 추출물이 염증을 유발하는 인터루킨-1β(IL-1β), 인터루킨-6(IL-6) 및 사이클로옥시게나아제(COX-2)의 생성 억제 효과가 매우 우수한 것을 확인할 수 있었으며, 이는 항염 효과를 지닌 갈산, 비-갈레이트 카테킨 및 플라보놀의 비당체의 함량이 증대된 것으로부터 기인된 것이라 할 수 있다.(IL-1?), Interleukin-6 (IL-6), and cyclooxygenase (COX-2), which induce inflammation, are produced by the green tea extract of Example 1 prepared by the production method of the present invention. , And this result can be attributed to the increase in the content of asparaginase of gallic acid, non-gallate catechin and flavonol having anti-inflammatory effect.
실험예 3. 플라보놀 비당체의 카테킨 흡수 측정Experimental Example 3 Measurement of Catechin Absorption of Flavonol Aggregate
상기 실시예 1에서 제조된 녹차 추출물의 플라보놀 비당체의 카테킨 흡수 정도를 측정하기 위하여, 상기 녹차 추출물로부터 플라보놀의 비당체를 분획하였다.In order to measure the degree of catechin absorption of the Flavonol anhydrides of the green tea extract prepared in Example 1, the Flavonol of the flavonol was fractionated from the green tea extract.
플라보놀의 비당체의 분획은 우선, 상기 실시예 1의 녹차 추출물 각각을 DMSO 및 메탄올 혼합용매(1:9, v/v)에 용해하여 20% 농도의 용액을 제조하였다. 그 후 컬럼(35x250mm, 10μm, C18)에 흡착시키고, 물 및 아세토니트릴의 농도 구배를 이용하여 얻어진 플라보놀의 비당체의 분획액을 농축 및 동결건조하였다.Flavonol fractions of flavonol were prepared by dissolving each of the green tea extracts of Example 1 in DMSO and methanol mixed solvent (1: 9, v / v) at a concentration of 20%. Thereafter, the filtrate was adsorbed on a column (35x250 mm, 10 mu m, C18), and a fraction of an unglycosylated flavonol obtained by using a concentration gradient of water and acetonitrile was concentrated and lyophilized.
인체 유래 대장암세포주(HT-29)에 에피카테킨이 35% 포함된 녹차 추출물을 넣었다. 실험군을 3개 군으로 나누어 대조군은 녹차추출물 이외에는 아무것도 처리하지 않고(blank), 양성 대조군으로 퀘르세틴을, 실험군으로 상기에서 얻어진 실시예 1의 플라보놀의 비당체 분획액을 각각 100ppm씩 첨가하여 1시간 동안 반응시켰다. 이후 세포를 PBS로 세척하고 90% 메탄올 및 10% DMSO의 혼합용액 500μL를 넣고 소니케이션을 통하여 세포를 분해하였고, 0.45μm PDVF 필터를 이용하여 불순물을 정제하고, HPLC를 이용하여 세포내 카테킨의 함량을 측정하였다.The green tea extract containing 35% of epicatechin was added to the human colon cancer cell line (HT-29). The experimental group was divided into three groups. In the control group, quercetin was added as a positive control and blank fraction of flavonol of Example 1 was added to the test group in an amount of 100 ppm each for 1 hour Lt; / RTI > Then, the cells were washed with PBS, 500 μL of a mixed solution of 90% methanol and 10% DMSO was added and the cells were disrupted by sonication. The impurities were purified using a 0.45 μm PDVF filter, and the content of intracellular catechin Were measured.
HPLC의 분석 조건은 상기 실험예 1과 동일하게 수행하였다.The analysis conditions of the HPLC were the same as those of Experimental Example 1 above.
그 결과, 복합효소를 사용한 본 발명의 제조방법으로 제조된 실시예 1의 녹차 추출물은 세포내 카테킨 흡수가 이루어진 것을 확인할 수 있었다(도 4).As a result, it was confirmed that the green tea extract of Example 1 prepared by the method of the present invention using the complex enzyme had intracellular catechin absorption (FIG. 4).
따라서, 본 발명의 제조방법으로 제조된 녹차 추출물은 플라보놀의 비당체의 함량이 증대되어 세포내 카테킨의 흡수를 촉진시켜주는 것을 알 수 있다.Therefore, it can be seen that the green tea extract prepared by the production method of the present invention promotes absorption of intracellular catechin by increasing the content of the irregular body of flavonol.
Claims (18)
- (a)녹차 추출물을 제조하는 단계; 및(a) preparing a green tea extract; And(b)상기 제조된 녹차 추출물 및 효소를 반응시키는 단계;를 포함하는(b) reacting the prepared green tea extract and an enzyme갈산, 비-갈레이트 카테킨 및 플라보놀의 비당체의 함량이 증대된 녹차 추출물 제조방법으로,A method for preparing green tea extract having increased content of non-saccharide of gallic acid, non-gallate catechin and flavonol,상기 효소는 글루카나아제 및 아라비나나아제를 포함하는 복합효소인 것을 특징으로 하는 녹차 추출물 제조방법.Wherein the enzyme is a complex enzyme comprising glucanase and arabinase.
- 청구항 1에 있어서, 상기 (a)단계의 녹차 추출물의 제조는 물, 탄소수 1 내지 5의 알코올 및 초산에틸로 이루어진 군으로부터 선택되는 1종 이상을 포함하는 추출용매를 사용하여, 상온 내지 80℃에서 1 내지 5시간 동안 수행되는 것을 특징으로 하는 녹차 추출물 제조방법.The method according to claim 1, wherein the preparation of the green tea extract of step (a) is carried out using an extraction solvent containing at least one selected from the group consisting of water, an alcohol having 1 to 5 carbon atoms and ethyl acetate, Wherein the extract is performed for 1 to 5 hours.
- 청구항 1에 있어서, 상기 복합효소는 상기 (a)단계의 녹차 추출물 총 중량에 대하여 3 내지 30 중량%로 포함되는 것을 특징으로 하는 녹차 추출물 제조방법.[Claim 3] The method according to claim 1, wherein the complex enzyme is contained in an amount of 3 to 30% by weight based on the total weight of the green tea extract of step (a).
- 청구항 1에 있어서, 상기 복합효소는 글루카나아제 및 아라비나나아제가 1:10 내지 10:1의 중량비로 혼합된 것을 특징으로 하는 녹차 추출물 제조방법.[Claim 2] The method according to claim 1, wherein the complex enzyme is a mixture of glucanase and arabinase in a weight ratio of 1:10 to 10: 1.
- 청구항 1에 있어서, 상기 (b)단계는 녹차 추출물 및 복합효소를 20 내지 60℃에서 12 내지 48시간 동안 반응시키는 것을 특징으로 하는 녹차 추출물 제조방법.[Claim 2] The method according to claim 1, wherein the step (b) comprises reacting the green tea extract and the complex enzyme at 20 to 60 DEG C for 12 to 48 hours.
- 청구항 1에 있어서, 상기 (b)단계는 녹차 추출물 및 복합효소를 반응시킨 후 효소를 실활시키는 단계를 추가로 포함하는 것을 특징으로 하는 녹차 추출물 제조방법.The method according to claim 1, wherein the step (b) further comprises the step of inactivating the enzyme after reacting the green tea extract and the complex enzyme.
- 청구항 6에 있어서, 상기 복합효소의 실활은 50 내지 90℃에서 10분 내지 3시간 동안 이루어지는 것을 특징으로 하는 녹차 추출물 제조방법.[Claim 6] The method according to claim 6, wherein the complex enzyme is inactivated at 50 to 90 DEG C for 10 minutes to 3 hours.
- 청구항 1에 있어서, 상기 (b)단계 후 당을 제거하는 단계를 추가로 포함하는 것을 특징으로 하는 녹차 추출물 제조방법.[Claim 3] The method according to claim 1, further comprising a step of removing sugar after step (b).
- 청구항 8에 있어서, 상기 당의 제거는 크로마토그래피를 이용하여 당을 분리하여 제거하는 것을 특징으로 하는 녹차 추출물 제조방법.[Claim 9] The method according to claim 8, wherein the saccharide is removed by separating sugar using chromatography.
- 청구항 1에 있어서, 상기 비-갈레이트 카테킨은 갈로카테킨, 에피갈로카테킨, 카테킨 및 에피카테킨을 포함하는 것을 특징으로 하는 녹차 추출물 제조방법.[2] The method according to claim 1, wherein the non-galactose catechin comprises gallocatechin, epigallocatechin, catechin and epicatechin.
- 청구항 1에 있어서, 상기 플라보놀의 비당체는 미리세틴, 퀘르세틴 및 캠페롤을 포함하는 것을 특징으로 하는 녹차 추출물 제조방법.[Claim 3] The method according to claim 1, wherein the unglycosylated form of flavonol comprises prednisine, quercetin and camphorol.
- 청구항 1에 있어서, 상기 갈산은 녹차 추출물 총 중량에 대하여 2 내지 10 중량%로 포함되며,[Claim 2] The method according to claim 1, wherein the gallic acid is contained in an amount of 2 to 10% by weight based on the total weight of the green tea extract,상기 비-갈레이트 카테킨은 녹차 추출물 총 중량에 대하여 20 내지 60 중량%로 포함되며, The non-galactose catechin is contained in an amount of 20 to 60% by weight based on the total weight of the green tea extract,상기 플라보놀의 비당체는 4 내지 15mg/g으로 포함되는 것을 특징으로 하는 녹차 추출물 제조방법.Wherein the Flavonol of the Flavonol is contained in an amount of 4 to 15 mg / g.
- 청구항 1 내지 12 중 어느 한 항의 제조방법으로 제조된 녹차 추출물.A green tea extract prepared by the method of any one of claims 1 to 12.
- 청구항 13에 있어서, 상기 녹차 추출물은[Claim 14] The method according to claim 13,녹차 추출물 총 중량에 대하여 갈산을 2 내지 10 중량%로 포함하며,And 2 to 10% by weight of gallic acid based on the total weight of the green tea extract,녹차 추출물 총 중량에 대하여 비-갈레이트 카테킨을 20 내지 60 중량%로 포함하며,And 20 to 60% by weight of non-gallate catechin based on the total weight of the green tea extract,플라보놀의 비당체를 4 내지 15mg/g으로 포함하는 것을 특징으로 하는 녹차 추출물.Wherein the green tea extract contains 4 to 15 mg / g of an irregular body of flavonol.
- 청구항 13에 있어서, 상기 녹차 추출물은 인터루킨-1β(IL-1β), 인터루킨-6(IL-6) 및 사이클로옥시게나아제-2(COX-2)로 이루어진 군으로부터 선택되는 1종 이상의 발현을 억제하는 것을 특징으로 하는 녹차 추출물.14. The method of claim 13, wherein the green tea extract inhibits expression of at least one selected from the group consisting of interleukin-1? (IL-1?), Interleukin-6 (IL-6), and cyclooxygenase- And extracting the green tea.
- 청구항 13의 녹차 추출물을 유효성분으로 포함하는 항염증용 화장료 조성물.A cosmetic composition for antiinflammation comprising the green tea extract of claim 13 as an active ingredient.
- 청구항 13의 녹차 추출물을 유효성분으로 포함하는 항염증용 약학 조성물.A pharmaceutical composition for antiinflammation comprising the green tea extract of claim 13 as an active ingredient.
- 청구항 13의 녹차 추출물을 유효성분으로 포함하는 항염증용 식품 조성물.13. An anti-inflammatory food composition comprising the green tea extract of claim 13 as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201880086051.7A CN111601582A (en) | 2017-11-14 | 2018-09-18 | Method for preparing green tea extract and green tea extract prepared thereby |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170151218A KR102394664B1 (en) | 2017-11-14 | 2017-11-14 | Method for manufacturing green tea extract, and green tea extract therefrom |
| KR10-2017-0151218 | 2017-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2019098518A1 true WO2019098518A1 (en) | 2019-05-23 |
Family
ID=66538712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2018/010949 WO2019098518A1 (en) | 2017-11-14 | 2018-09-18 | Method for preparing green tea extract and green tea extract prepared therefrom |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR102394664B1 (en) |
| CN (1) | CN111601582A (en) |
| WO (1) | WO2019098518A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102533910B1 (en) * | 2020-08-21 | 2023-05-18 | 수산업협동조합중앙회 | A preparation method of green tea concentrate with high fishy smell control effect and a preparation mehod of fish with suppressed fishy smell using it |
| KR20220101432A (en) * | 2021-01-11 | 2022-07-19 | (주)아모레퍼시픽 | Composition for reducing body fat comprising green tea extract containing gallocatechin gallate as an active ingredient and manufacturing method thereof |
| KR20220145604A (en) | 2021-04-22 | 2022-10-31 | (주)아모레퍼시픽 | Composition for inhibiting sugar absorption |
| WO2023002500A1 (en) * | 2021-07-19 | 2023-01-26 | Council Of Scientific & Industrial Research | Single process for sequential extraction of products from green tea leaves |
| KR20230166395A (en) | 2022-05-30 | 2023-12-07 | (주)아모레퍼시픽 | Composition for reducing the absorption of microplastics |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007274920A (en) * | 2006-04-04 | 2007-10-25 | Kao Corp | Method for producing green-tea extract |
| KR101391063B1 (en) * | 2006-04-17 | 2014-04-30 | 카오카부시키가이샤 | Process for producing purified green tea extract |
| KR101420000B1 (en) * | 2012-04-05 | 2014-07-17 | 강원대학교산학협력단 | Method for extracting methylated catechins from tea leaves, green tea or oorong tea |
| CN105367679A (en) * | 2015-12-03 | 2016-03-02 | 镇江市丹徒区南山溪园茶叶专业合作社 | Green tea polysaccharide extraction method |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4244230B2 (en) * | 2006-03-02 | 2009-03-25 | 花王株式会社 | Method for producing purified tea extract |
| JP5517412B2 (en) * | 2007-05-24 | 2014-06-11 | 花王株式会社 | Purified green tea extract |
| JP5411748B2 (en) * | 2010-03-05 | 2014-02-12 | 長谷川香料株式会社 | Production method of tea extracts |
| KR20130070107A (en) * | 2011-12-19 | 2013-06-27 | 주식회사 메디코스텍 | A method for preparing functional green tea extract comprising abundant functional ingredient and the cosmetic composition comprising the same having potent anti-wrinkle activity |
| JP6338918B2 (en) * | 2014-04-17 | 2018-06-06 | 長谷川香料株式会社 | Method for producing green tea extract |
-
2017
- 2017-11-14 KR KR1020170151218A patent/KR102394664B1/en active IP Right Grant
-
2018
- 2018-09-18 CN CN201880086051.7A patent/CN111601582A/en active Pending
- 2018-09-18 WO PCT/KR2018/010949 patent/WO2019098518A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007274920A (en) * | 2006-04-04 | 2007-10-25 | Kao Corp | Method for producing green-tea extract |
| KR101391063B1 (en) * | 2006-04-17 | 2014-04-30 | 카오카부시키가이샤 | Process for producing purified green tea extract |
| KR101420000B1 (en) * | 2012-04-05 | 2014-07-17 | 강원대학교산학협력단 | Method for extracting methylated catechins from tea leaves, green tea or oorong tea |
| CN105367679A (en) * | 2015-12-03 | 2016-03-02 | 镇江市丹徒区南山溪园茶叶专业合作社 | Green tea polysaccharide extraction method |
Non-Patent Citations (1)
| Title |
|---|
| LEE LAN SOOK ET AL.: "High quality green tea extract production from enzyme treated fresh green tea leaves", JOURNAL OF KOREAN SOCIETY OF FOOD SCIENCE AND NUTRITION, vol. 37, no. 8, 30 August 2008 (2008-08-30), pages 1025 - 1026, XP053026848 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102394664B1 (en) | 2022-05-06 |
| CN111601582A (en) | 2020-08-28 |
| KR20190054542A (en) | 2019-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019098518A1 (en) | Method for preparing green tea extract and green tea extract prepared therefrom | |
| AU628514B2 (en) | Inhibitive agent against activity of alpha-amylase | |
| WO2014084572A1 (en) | Catechin bioavailability enhancer comprising cyclodextrin | |
| WO2013180526A1 (en) | Skin regeneration and hair growth promoter containing edelweiss extract | |
| WO2019088412A1 (en) | Composition containing tea extract with increased specific ingredient content for prevention or alleviation of lipid metabolism disorders | |
| WO2022177215A1 (en) | Method for promoting antioxidant activity of purple tea leaves | |
| WO2022181936A1 (en) | Composition inhibiting muscle loss or promoting muscle formation through skin-derived exosomes | |
| US9132159B2 (en) | Composition for prevention and/or treatment of tumors containing acacia derivative | |
| KR20190013575A (en) | composition for preventing of hair loss or promoting hair growth | |
| WO2016056781A1 (en) | Composition for hair loss prevention or hair growth stimulation comprising artemisia umbelliformis extract | |
| WO2024071736A1 (en) | Pharmaceutical composition for prevention or treatment of allergic diseases, containing dead cells of streptococcus pyogenes or spea protein | |
| WO2019093651A1 (en) | Method for preparing fermented-green-tea extract and fermented-green-tea extract prepared thereby | |
| WO2018111042A2 (en) | Cosmetic composition comprising extract of medicinal herbs as active ingredient | |
| WO2020138834A1 (en) | Composition for preventing or treating skin diseases comprising bridalwreath spirea | |
| WO2016056780A1 (en) | Composition for hair loss prevention or hair growth stimulation comprising scutellaria alpina extract | |
| WO2019212300A1 (en) | Composition comprising aster koraiensis nakai extract or fraction thereof as effective ingredient for prevention or treatment of parkinson's disease | |
| WO2019139403A1 (en) | Composition containing sericin, torilis japonica extract, and viscum album extract for skin generation, skin soothing, or wound healing | |
| WO2019031655A1 (en) | Composition comprising thymol as effective ingredient for preventing or treating skin wrinkle or atopic dermatitis | |
| WO2021215882A1 (en) | Composition for preventing hair loss or promoting hair growth comprising camellia pericarp extract as active ingredient | |
| WO2021080298A1 (en) | Composition containing enteroccocus faecalis as active ingredient for preventing or treating obesity or metabolic syndromes induced thereby | |
| WO2016117762A1 (en) | Composition containing gooseberry extract or glutathione | |
| WO2020096299A1 (en) | Green tea extract having modified constituent content and composition comprising same | |
| WO2019245245A1 (en) | Pharmaceutical composition for preventing and treating liver damage comprising turmeric extract | |
| WO2018016783A1 (en) | Moisturizing composition containing 3-o-galloyl-3,3',5,5',7-pentahydroxyflavan | |
| JP2021066673A (en) | Allergic rhinitis symptom inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18878039 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 18878039 Country of ref document: EP Kind code of ref document: A1 |